NEW YORK (GenomeWeb News) — Diagnostics technologies developer Avacta Group and the University of Liverpool will collaborate to develop integrated microarray and mass spectrometry tools for use in detecting biomarkers and discovering new drug targets.

Wetherby, UK-based Avacta said today the partners will combine the firm's engineered affinity reagent microarrays, which it calls Affimer microarrays, and reagents with mass spectrometry tools developed by University of Liverpool Professor Rob Beynon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.